| Revenue growth | 32.9% YoY for Q4 FY26; 23.9% for full year FY26. |
|---|---|
| Margins | EBITDA margin improved to 29.4% in Q4 FY26 from 23.2% YoY. |
| Demand visibility | Strong US demand for complex products like Tiotropium and Albuterol. |
| Management confidence | High confidence in complex generic and biosimilar pipeline strategy. |
Growth
Q4 FY26 Revenue grew 32.9% YoY; EBITDA increased 68.0% YoY; Net Income rose 89.0% YoY.
Outlook
Plan to launch 20+ products in India FY27; targeting 100+ new product launches in US by FY31.
Risks
Price erosion in Albuterol and US base business competition; regulatory remediation ongoing at Pithampur Unit II.
Earnings Call filed with BSE, NSE: LUPIN. Summary written with AI assistance from the document.
Lupin Ltd: key numbers
- Share price
- ₹2,012.90
- Market cap
- ₹92,048 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 16.6×Sector 47.3×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Employee Stock Options
Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Employee Stock Options
Lupin Limited allotted 30,967 equity shares under its Employee Stock Option Plan. This allotment increases the company's total issued and paid-up equity share capital.
Lupin Other Announcement
Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.
Lupin Partnership
Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.
- Value
- ₹832.5 Cr
- Execution
- Initial term until 20th anniversary of first commercial sale
Lupin Management Change
Lupin Limited announced the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026.